Impact of Histological Features on Adjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Carcinoma

Background/Aim: This study evaluated the efficacy of adjuvant chemotherapy (AC) for intraductal papillary mucinous carcinoma (IPMC). Patients and Methods: We retrospectively analyzed patients who underwent pancreatectomy for invasive IPMC from January 2007 to June 2020. We evaluated outcomes of AC in the entire cohort and in patients with known prognostic factors. Results: A total of 51 patients with invasive IPMC underwent surgery, of which 35 received AC. In the entire cohort, there was no significant difference in median overall survival (OS) between the AC and surgery alone (SA) group [hazard ratio (HR)=0.54; p=0.232]. For patients with poorly differentiated adenocarcinoma, median OS was significantly longer in the AC group (HR=0.27; p=0.022). For patients with lymph node metastasis, median OS was significantly higher in the AC group (HR=0.07; p<0.001). Conclusion: AC may be effective for selected invasive IPMC patients.

[1]  H. Seo,et al.  Role of postoperative adjuvant therapy in resected invasive intraductal papillary mucinous neoplasm of the pancreas: A multicenter external validation , 2021, Journal of hepato-biliary-pancreatic sciences.

[2]  S. Ahrendt,et al.  Controversial Role of Adjuvant Therapy in Node-Negative Invasive Intraductal Papillary Mucinous Neoplasm , 2020, Annals of Surgical Oncology.

[3]  Jeffrey W. Clark,et al.  Impact of adjuvant therapy in patients with invasive intraductal papillary mucinous neoplasms of the pancreas. , 2020, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[4]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[5]  R. Andersson,et al.  Adjuvant therapy in invasive intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a systematic review. , 2019, Annals of translational medicine.

[6]  T. Ohtsuka,et al.  Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society , 2019, Journal of Gastroenterology.

[7]  F. Fujita,et al.  Expression of Matrix Metalloproteinases in Intraductal Papillary Mucinous Neoplasm of the Pancreas , 2019, AntiCancer Research.

[8]  C. Bassi,et al.  Adjuvant chemotherapy is associated with improved postoperative survival in specific subtypes of invasive intraductal papillary mucinous neoplasms (IPMN) of the pancreas: it is time for randomized controlled data. , 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[9]  Jin‐Young Jang,et al.  of the pancreas , 2017 .

[10]  Mithat Gönen,et al.  Multi-institutional Validation Study of the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in Patients With Pancreatic Adenocarcinoma , 2017, Annals of surgery.

[11]  N. Sata,et al.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.

[12]  D. Fraker,et al.  The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN) , 2016, Cancer.

[13]  Jin‐Young Jang,et al.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting. , 2016, Annals of surgery.

[14]  Z. Fong,et al.  Intraductal Papillary Mucinous Adenocarcinoma of the Pancreas: Clinical Outcomes, Prognostic Factors, and the Role of Adjuvant Therapy , 2011, Visceral Medicine.

[15]  N. Funel,et al.  Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms. , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[16]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[17]  R. Pietrobon,et al.  Adjuvant Radiotherapy in the Treatment of Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas: an Analysis of the Surveillance, Epidemiology, and End Results Registry , 2012, Annals of Surgical Oncology.

[18]  Joshua A. Waters,et al.  Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. , 2011, Journal of the American College of Surgeons.

[19]  D. Sahani,et al.  Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes , 2011, Gut.

[20]  Joshua A. Waters,et al.  Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. , 2010, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[21]  J. Cameron,et al.  Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. , 2010, International journal of radiation oncology, biology, physics.

[22]  Peter Neuhaus,et al.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.

[23]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[24]  S. Saglam,et al.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[26]  D. Klimstra,et al.  Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. , 1996, Annals of surgery.

[27]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.